Patient Case: 37-Year-Old Adult Female With a Long History of ADHD Treatment

PATIENT CASE

Review the clinical considerations, therapeutic history, and need for symptom improvement that led to nonstimulant ADHD treatment for 37-year-old Jennifer.

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

Please see full Important Safety Information to the top left.

 JENNIFER, 37 YEARS OLD  

❯ Current ADHD treatment: none, recently discontinued treatment with a stimulant

❯ Ongoing struggles with focus, task completion, and attention to detail: talked to her doctor about an adjustment to her ADHD treatment plan

Based on a real patient story. Patient name and images have been changed. Individual results may vary.
 

 CLINICAL CONSIDERATIONS:  

• Patient tried stimulant medications on and off but would not “feel like herself” and discontinued treatment
• Reported “getting by” over the years without treatment—but recent struggles to focus, stay on task, and manage work and home life prompted reevaluation of treatment
• Constantly feeling overwhelmed before meetings at work or at the end of the day during dinner and bedtime for her children
   

 JENNIFER'S THERAPEUTIC HISTORY:  

• Treated for ADHD on and off from childhood but struggled with adherence due to tolerability issues
• Recently discontinued another stimulant treatment 
• No history of substance abuse
   

 JENNIFER'S NEED FOR SYMPTOM IMPROVEMENT:  

• Initial consultation was for ADHD evaluation
  • Patient works with an ADHD coach and sees her long-term therapist
• AISRS score at first visit was 42 (markedly ill)
• Marked impairment on the CGI-S
• Previous history and tolerability concerns with stimulants prompted a discussion around alternate treatment options
   

 TREATMENT WITH QELBREE¹:  

• Patient was started on Qelbree 200 mg; discussed ability to titrate the dose between 200 mg and 600 mg as needed
  • Patient was encouraged to check in via phone at 2 weeks to discuss any concerns and treatment progress
  • Patient scheduled 1-month follow-up appointment
• At 1-month follow-up, AISRS score showed improvement, with a score of 29 (moderately ill); patient was taking Qelbree 400 mg/day:
  • Patient reported an improved ability to focus, think clearly, and stay on task
  • In Jennifer’s words, “It was like someone came along and parted the cobwebs before me, clearing a straight, bright path—the cobwebs dangling to each side no longer blocking my way.”
• At 4 months, patient was still on 400 mg/day:
  • AISRS score showed further improvement, with a score of 23

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AISRS, Investigator Symptom Rating Scale; CGI-S, Clinical Global Impression–Severity of Illness

IMPORTANT SAFETY INFORMATION

• Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
   

Please see full Important Safety Information to the top left.

Please see full Prescribing Information, including Boxed Warning.

Learn more about Qelbree at QelbreeHCP.com.

Reference:

1. Qelbree [package insert]; Rockville, MD; Supernus Pharmaceuticals, Inc.

QBE.2023-0202